SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic solid tumor cancers SYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic solid tumor cancers

Continued here:
Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant...